Detalhe da pesquisa
1.
Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell
; 185(12): 2116-2131.e18, 2022 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35662412
2.
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.
Cell
; 185(14): 2422-2433.e13, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35772405
3.
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
Cell
; 184(9): 2348-2361.e6, 2021 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730597
4.
Antibody evasion by the P.1 strain of SARS-CoV-2.
Cell
; 184(11): 2939-2954.e9, 2021 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33852911
5.
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
Cell
; 184(16): 4220-4236.e13, 2021 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34242578
6.
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
Cell
; 184(8): 2201-2211.e7, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33743891
7.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Lancet
; 399(10342): 2212-2225, 2022 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35691324
8.
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Lancet
; 399(10324): 521-529, 2022 02 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35074136
9.
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Clin Exp Immunol
; 211(3): 280-287, 2023 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729167
10.
Genetic Susceptibility to Enteric Fever in Experimentally Challenged Human Volunteers.
Infect Immun
; 90(4): e0038921, 2022 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35254093
11.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
; 398(10304): 981-990, 2021 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480858
12.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Lancet
; 397(10282): 1351-1362, 2021 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33798499
13.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet
; 397(10269): 99-111, 2021 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33306989
14.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33220855
15.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet
; 397(10277): 881-891, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617777
16.
Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR.
J Clin Microbiol
; 60(4): e0228321, 2022 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35321556
17.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Lancet
; 396(10249): 467-478, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32702298
18.
Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease.
Nat Commun
; 15(1): 3402, 2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38649734
19.
Antiviral responses induced by Tdap-IPV vaccination are associated with persistent humoral immunity to Bordetella pertussis.
Nat Commun
; 15(1): 2133, 2024 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38459022
20.
Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.
Hum Vaccin Immunother
; 19(2): 2233400, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37438960